High Blood Pressure and Life Expectancy: What Studies Show

What the research shows about high blood pressure, longevity, and the years treatment may help protect.

You cannot change your age or family history. Blood pressure is different: it is a major cardiovascular risk factor that treatment can change. Bringing it down prevents heart attacks, strokes, heart failure, and early death. That makes a high reading worth addressing even when you feel completely well.[4][5]

The useful question is how your next steps can change your future.

Educational use only. This article provides general health information. It does not constitute medical advice or medical care and does not replace individualized guidance, diagnosis, or treatment from your clinician. Do not start, stop, or change medication based on this article alone.

The 30-second takeaway

• Hypertension is linked to shorter life and earlier cardiovascular disease. Some long-term studies find a difference of roughly five years, but that is a population comparison, not a personal forecast.
• Treatment changes outcomes. Across randomized trials, lowering systolic pressure—the top number—by 5 mm Hg reduced major cardiovascular events by about 10% in relative terms.[5]
• Benefits begin early. A large 2026 analysis found protection emerging within the first months of treatment.[14]
• Sustained control is the goal. A reliable home average and a treatment plan you can maintain matter more than one perfect reading.

What high blood pressure costs over a lifetime

Blood pressure damages arteries quietly. By the time it causes symptoms, an opportunity for prevention may already have been missed. Long-term studies help show what that exposure can mean.

In the Framingham Heart Study, people with normal blood pressure at age 50 had roughly five more years of life expectancy than those with hypertension: 5.1 years for men and 4.9 for women.[1] A 2026 analysis of middle-aged and older Chinese adults found a similar pattern, estimating a gap of about 5.75 years at age 45 and 4.79 years at age 65.[10]

These studies compare groups; they do not show that everyone diagnosed today will lose five years. Historical treatment patterns, other risks, and how long blood pressure has been elevated all affect the result. They also do not mean treatment automatically restores exactly five years.

There is another cost beyond total lifespan: illness arriving earlier. In a study of 1.25 million people, hypertension was associated with cardiovascular disease developing about five years earlier in estimates beginning at age 30.[2] Those are years free of cardiovascular disease, rather than years of total life lost. Protecting those years can mean more time walking without limitation, working, traveling, and living independently.

The pressure you accumulate matters

A blood-pressure reading is a snapshot. Your arteries experience the whole history.

Among 11,502 middle-aged adults from five U.S. cohorts, lower cumulative systolic pressure over the preceding decade was associated with longer survival and later cardiovascular disease.[3] This is why prevention is worth starting before symptoms appear, and why a reassuring reading today does not erase years of prior exposure.

Past exposure also does not make treatment futile. The useful question is what happens to your pressure from here.

Every point counts

A major analysis combined 48 randomized trials and more than 340,000 people. Each 5 mm Hg reduction in systolic pressure reduced major cardiovascular events by about 10%, whether or not people already had cardiovascular disease.[5]

That is a relative reduction, not a ten-percentage-point drop in everyone's risk. Someone starting at higher risk generally has more events to prevent and a larger absolute benefit.

The practical message is encouraging: you do not need to reach a perfect number before improvement counts. A sustained reduction from 150 to 140 can matter. So can a further reduction when it is appropriate and well tolerated. The trial average is not an instruction to lower your own pressure by a fixed amount; it is evidence that meaningful progress has value.

The proof: what happens when people are treated

Observational studies describe risk. Randomized trials test whether treatment changes it.

SPRINT enrolled 9,361 adults aged 50 or older at increased cardiovascular risk, without diabetes or a previous stroke. In the initial report, targeting systolic pressure below 120 rather than below 140 reduced the trial's major cardiovascular outcome by about 25% and deaths from any cause by about 27% over a median 3.26 years.[4] The final report confirmed the benefit, with updated relative reductions of 27% and 25%, respectively.[9]

To put the first result in perspective, major events occurred at rates of 1.65% versus 2.19% per year. That is an absolute difference of 0.54 percentage points per year during the trial—not a 25-percentage-point reduction for each participant.[4]

Other trials broadened the picture:

• STEP: Among adults aged 60–80 in China, a target of 110–129 rather than 130–149 reduced the trial's cardiovascular outcome by 26%; events occurred in 3.5% versus 4.6% over a median 3.34 years.[11]
• ESPRIT: In 11,255 higher-risk adults in China, including people with diabetes or a prior stroke, a target below 120 rather than below 140 reduced major cardiovascular events by 12%.[12]
• BPROAD: In 12,821 adults with type 2 diabetes and elevated cardiovascular risk in China, targeting below 120 rather than below 140 reduced major cardiovascular events by 21%.[13]

These trials used different populations and outcome definitions; the percentages are not a ranking of which strategy works best. Together, they make the case that treating high blood pressure can prevent serious illness.

Lower targets also require monitoring. SPRINT found more hypotension, fainting, electrolyte abnormalities, and acute kidney injury with intensive treatment. The aim is a target that improves outcomes and is appropriate for the person—not the lowest reading at any cost.[9]

How many years can treatment give back?

Trials cannot follow every participant for a lifetime, so researchers use models to estimate what their results might mean over longer periods.

One analysis using SPRINT data estimated that intensive rather than standard control could add about 2.9 years of life at age 50, 1.1 years at age 65, and 0.8 years at age 80 in SPRINT-like patients.[6] Those are modeled estimates with uncertainty, not extra years directly observed or guaranteed to an individual.

Healthy years matter too. A simulation based on the Jackson Heart Study estimated that preventing hypertension among Black adults could improve both total life expectancy and years without cardiovascular disease.[16] Prevention and treatment are different questions, but both point toward a worthwhile goal: more years lived without stroke or heart failure.

The promise is not a particular birthday. It is a better chance of reaching later life with the health to enjoy it.

Why keeping it controlled matters

One good reading is useful information. A sustained pattern is what a prevention plan is trying to achieve.

A 2026 meta-analysis of 51 trials involving more than 358,000 people found that cardiovascular benefits began early. The relative effect did not grow progressively larger with each additional year, but cumulative absolute benefit continued to increase with longer treatment.[14] Put simply, continued control allows more events to be prevented over time.

Longer follow-up of SPRINT also reinforces the importance of maintaining control: after the randomized treatment period ended and the blood-pressure difference narrowed, the mortality advantage was not sustained over the longer follow-up.[15] That does not establish that all prior benefit disappears when treatment changes. It means an earlier period of good control is not a reason to ignore high readings later.

A normal reading while taking medication often means the plan is working. If side effects, cost, or a complicated schedule make that plan difficult, bring the problem to your clinician. A sustainable plan is more useful than a theoretically ideal one you cannot maintain.

What you can do, starting this week

You do not need to change everything at once. Choose one manageable step:

1. Get a trustworthy average. Use a validated upper-arm monitor with the right cuff size and follow a consistent routine. The home blood-pressure guide explains how.
2. Make one repeatable lifestyle change. Replace a high-sodium food, begin regular activity you can sustain, or work toward a DASH-style eating pattern. The main blood-pressure guide explains the options and their expected effects.
3. Review your target and treatment. Bring your readings, medication list, and any side effects to your clinician. Many people need more than one medicine; that is common and is not a personal failure.

Potassium supplements and potassium-based salt substitutes need a separate check if you have kidney disease or take medicines that raise potassium. “Heart healthy” on a label does not make a product appropriate for everyone.[8]

Know your target—and when to get help

For most adults with hypertension, the 2025 U.S. guideline recommends a goal below 130/80 mm Hg. More intensive systolic targets below 120 are encouraged in selected higher-risk groups when appropriate and tolerated. Your clinician should help choose the goal and monitoring plan, especially with frailty, dizziness, kidney disease, or other competing concerns.[8]

Judge control from repeated measurements rather than one reading. Report lightheadedness, fainting, or other treatment difficulties instead of changing doses on your own.

This is a long-term prevention article. If you have a very high reading or new symptoms, use the separate blood-pressure emergency guide. Chest pain, stroke symptoms, or severe breathing difficulty require emergency help regardless of the number.

Frequently asked questions

How many years does high blood pressure take off your life?

There is no personal number that can be calculated from a reading. Some cohort studies show gaps of roughly five years between blood-pressure groups in middle age. Age, duration, treatment, and other risks change the picture. Those averages are a reason to act, not a forecast of your lifespan.[1][10]

Can I live a long life with hypertension?

Yes. Hypertension increases risk; it does not fix your lifespan. Sustained control, alongside attention to cholesterol, blood sugar, activity, and tobacco exposure, can meaningfully improve your outlook.

Is it too late to treat high blood pressure when I am older?

No. Trials including older adults show that treatment can prevent cardiovascular events. The target should reflect overall health, frailty, tolerability, and the person's priorities; age alone does not make prevention pointless.[11]

Does a lower blood pressure always mean a longer life?

No. A lower target must be appropriate and tolerated. Low-pressure symptoms, kidney effects, medication burden, and other health conditions matter. Treatment aims to reduce illness and preserve health, not chase a number.[8][9]

If my blood pressure is normal now, can I stop medication?

Not on your own. A normal reading often means treatment is working. Discuss changes with your clinician, including whether lifestyle changes, side effects, or other circumstances call for a supervised adjustment.

Are the SPRINT survival gains guaranteed?

No. The extra years were modeled from trial data, not observed over participants' entire lifetimes. They describe estimates for a particular population, with uncertainty. The direct trial evidence is that treatment prevented cardiovascular events and deaths during follow-up.[6][9]

Your next step

Find your home average. Choose one change you can repeat. Arrange a conversation about your target and how to reach it safely.

High blood pressure is worth taking seriously because treatment works. Each sustained improvement is a chance to prevent illness and protect more healthy years.

References

1. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46:280–286. Study.

2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899–1911. Study.

3. Reges O, et al. Association of cumulative systolic blood pressure with long-term risk of cardiovascular disease and healthy longevity: findings from five U.S. cohorts. Hypertension. 2021. Study.

4. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. Trial.

5. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021. Meta-analysis.

6. Vaduganathan M, Claggett BL, Juraschek SP, Solomon SD. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of SPRINT. JAMA Cardiol. 2020. Modeling study.

7. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8:9418. Study.

8. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 multisociety guideline for high blood pressure in adults. J Am Coll Cardiol. 2025. Guideline.

9. SPRINT Research Group; Lewis CE, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921–1930. Final report.

10. Yuan K, Huang Y, Song J, et al. A prospective study on the association between hypertension, high-normal blood pressure, and life expectancy in middle-aged and elderly Chinese adults: findings from CHARLS. BMC Public Health. 2026. Study.

11. Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–1279. STEP trial.

12. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke. Lancet. 2024;404:245–255. ESPRIT trial.

13. Bi Y, Li M, Liu Y, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025;392:1155–1167. BPROAD trial.

14. Yang Q, Bidel Z, Canoy D, et al. A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials. Nat Med. 2026. Meta-analysis.

15. Jaeger BC, et al. Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022;7:1138–1146. Study.

16. Foti K, Zhang Y, Hennessy SE, et al. Hypertension prevention and healthy life expectancy in Black adults: the Jackson Heart Study. Hypertension. 2025;82:1095–1105. Modeling study.

Related reading

• Blood pressure: what your numbers mean
• How to check blood pressure at home
• High blood pressure stages
• When is high blood pressure an emergency?